Drug Formulary Committee: Minutes of March 11, 2015 Public Meeting

Members in attendance
Stacey Ness, Pharm.D., Kelly Ruby, Pharm.D., Al Heaton, RPh., Kathryn Lombardo, M.D., Monica Brands, Pharm.D., James Phillips, M.D., Margaret Artz, RPh, Ph.D., Stuart Williams, J.D., William Korchik, M.D.

DHS staff present
Adam Pavek, PharmD., Sara Drake, RPh., MPH, MBA

Others in attendance
Arian Casey, Pharm.D, Nina Bandali, Pharm.D.

Report of the Chair
In respect of time the chair bypassed the report of the chair.

Approval of the minutes
Minutes from the October 2014 meeting were reviewed and approved.

Old Business
None

New Business

Pharmacy Program Overview - 2014
Sara Drake, Pharm.D., MPH completed a 20 min review of DHS’s Fee-for-Service Pharmacy program performance of 2014. In 2014 enrollment, utilization and reimbursement increased while net spend per user per month has remained relatively flat. Prices for branded drugs are up 128% since 2006 with Specialty Drugs accounting for 1.5% of utilization but more than 25% of total pharmacy spend. Overall, the high cost of brand drugs has been offset by increased generic utilization.


OTC Formulary Addition: Lidocaine 4% Cream
The committee recommended the addition of OTC lidocaine 4% cream to the OTC formulary in the smallest package size available.
Class Review: Hepatitis C
The committee discussed the Hepatitis C class of drugs including Viekira Pak, Harvoni, Sovaldi, and Olysio. The Department recommended adopting the prior authorization criteria for MHCP fee-for-service treatment policy. The committee agreed with the department’s proposed policy with an amendment to require chemical dependency providers to attest to recipient abstinence of IV drug or alcohol use rather than the prescriber and added a requirement for prescribers to submit the outcomes of treatment (SVR12) to the Department 12 weeks after treatment completion. The committee determined the products in the Hepatitis C class to be therapeutically non-inferior to each other and recommended to manage the class based on cost. The committee recommended to the department that the category be managed based on cost and that the proposed prior authorization criteria with amendments be adopted by a unanimous vote.

New Specialty Drugs for Continued PA
The committee discussed Akynzeo (netupitant and palonosetron capsule)
The committee recommended to the department that Akynzeo remain on PA by a unanimous vote.

The committee discussed Esbriet (pirfenidone capsule)
The committee recommended to the department that Esbriet remain on PA by a unanimous vote.

The committee discussed Harvoni (ledipasvir and sofosbuvir tablet, film coated)
The committee recommended to the department that Harvoni remain on PA and be managed as part of the Hepatitis C class by a unanimous vote.

The committee discussed Ilevro (fentanyl citrate)
The Department recommended that Ilevro prior authorization be removed. The committee agreed with the recommendation that Ilevro PA be removed by a unanimous vote.

The committee discussed Jardiance (empagliflozin tablet, film coated)
The committee recommended to the department that Jardiance remain on PA by a unanimous vote.

The committee discussed Keytruda (pembrolizumab injection)
The committee recommended to the department that Keytruda remain on PA by a unanimous vote. The committee recommended that clinical criteria follow NCCN guidance.

The committee discussed Lemtrada (alemtuzumab injection)
The committee recommended to the department that Lemtrada remain on PA by a unanimous vote. The committee recommended that the drug be kept to on-label use.

The committee discussed Ofev (nintedanib capsule)
The committee recommended to the department that Ofev remain on PA by a unanimous vote.

The committee discussed Oralair
The committee recommended to the department that Oralair remain on PA by a unanimous vote.

The committee discussed Orfadin (nitisinone capsule)
The committee recommended to the department that Orfadin remain on PA by a unanimous vote.
The committee discussed Plegridy/Plegridy Pen (peginterferon beta-1a)
The committee recommended to the department that Plegridy/Plegridy Pen remain on PA by a unanimous vote. The committee recommended that clinical criteria require the trial and failure of interferon beta-1a.

The committee discussed Rasuvo (methotrexate sodium injection)
The committee recommended to the department that Rasuvo remain on PA by a unanimous vote.

The committee discussed Trulicity (dulaglutide injection)
The committee recommended to the department that Trulicity remain on PA by a unanimous vote. The committee recommended that clinical criteria require trial and failure of Byetta.

The committee discussed Tybost (cobicistat tablet)
The committee recommended to the department that Tybost remain on PA by a unanimous vote.

Tyvaso was removed from the DFC agenda. The product had already been reviewed by the committee.

The committee discussed Viekira Pak (dasabuvir and ombitasvir and paritaprevir and ritonavir)
The committee recommended to the department that Viekira Pak remain on PA and be managed as part of the Hepatitis C class by a unanimous vote.

The committee discussed Zydelig (idelalisib tablet)
The committee recommended to the department that Zydelig remain on PA by a unanimous vote.

Adjournment
The meeting was adjourned at 9:35 pm CST.